HERO LAB · NCT07640685
The Magnesium
Formulation Study
Three groups. Five weeks. A closer look at sleep, recovery, and performance in UCLA varsity athletes.
View trial registrationDoes the formulation
make a difference?
This randomized, blinded study compares magnesium glycinate and magnesium L-threonate with a matching placebo, following athletes in daily life and through structured testing.
The primary question: does sleep efficiency change from the baseline week to the final treatment week?
- Enrollment target
- 150 athletes
- Population
- UCLA varsity
- Assignment
- Randomized 1:1:1
- Study format
- Blinded, placebo-controlled
From starting point
to final measurement.
One baseline week. Four treatment weeks.
WHOOP monitoring throughout.
Two formulations.
One matching placebo.
Participants are randomly assigned in equal proportions. Treatment assignment is blinded.
The study is designed to evaluate these questions; results are not yet available.
- 01
Magnesium glycinate
Study formulation
- 02
Magnesium L-threonate
Study formulation
- 03
Matching placebo
Comparison group
First, establish
the starting point.
One week of wearable monitoring provides each athlete’s reference for sleep and recovery, before treatment begins.
Baseline assessments also establish starting performance measures.
The five-week study
- BBaseline
- 1Week 1
- 2Week 2
- 3Week 3
- 4Week 4
Baseline sleep efficiency is compared with the final treatment week.
Nightly capsules.
Daily-life monitoring.
Participants take their assigned study capsules nightly for four weeks, while WHOOP monitoring continues.
Brief daily surveys and weekly adherence and safety check-ins support follow-up.
The five-week study
- BBaseline
- 1Week 1
- 2Week 2
- 3Week 3
- 4Week 4
Nightly study capsules during weeks 1–4.
Sleep at the center.
Primary outcomeChange in WHOOP-derived sleep efficiency from the baseline week to the final treatment week.
Performance assessments compare baseline and final testing.
Recovery + performance
- Sleep duration and consistency
- HRV, resting heart rate, and WHOOP Recovery Score
- Reaction-time performance
- VALD grip-strength and countermovement-jump testing
Study visits, eligibility, capsule instructions, and participation requirements are confirmed by the study team. Read the registered protocol

The study continues
beyond the lab.
WHOOP monitoring follows sleep and recovery across the baseline and treatment periods, giving the research team repeated measurements during athletes’ daily lives.
- Sleep
- Sleep efficiency is the primary outcome. Duration and consistency provide additional context.
- Recovery
- HRV, resting heart rate, and WHOOP Recovery Score are secondary measures.
- Performance
- Structured reaction-time and VALD testing complement wearable monitoring.
These measurements describe the study outcomes; results are not yet available.
Ask about participation.
The Fall 2026 study is in progress. Current UCLA varsity athletes aged 18–35 who are actively training or competing can contact the study team to ask about eligibility and any current openings.
- Time commitment
- Approximately five weeks: one baseline week and four treatment weeks.
- What is involved
- Baseline and final testing, nightly assigned study capsules for 28 days, wearable monitoring, daily surveys, and weekly adherence and safety check-ins.
- Location
- UCLA in Los Angeles. The team will confirm where to attend.
- Before you enroll
- Ask about the exact number and length of visits, attendance arrangements, and compensation.
This overview reflects registered participation criteria checked October 10, 2026; additional screening criteria apply. The registry’s June 11 update still lists the study as not yet recruiting. Current study-team records show Fall 2026 participation in progress. Contact the team for current openings; this page does not guarantee enrollment.
You can also email jswisher@mednet.ucla.edu.
A new study. A separate trial.
This formulation study (NCT07640685) is distinct from HERO Lab’s original magnesium L-threonate trial (NCT07015047). Explore the earlier MgT study
Study design is based on the ClinicalTrials.gov record checked October 10, 2026. The in-progress Fall 2026 status reflects current study-team records. The WHOOP partnership reflects updates from the HERO Lab study team. The product image is illustrative.